33183 Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial
Mesinkovska N, Shapiro J, King B. 33183 Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial. Journal Of The American Academy Of Dermatology 2022, 87: ab54. DOI: 10.1016/j.jaad.2022.06.249.Peer-Reviewed Original Research